Diabetologia

, Volume 20, Issue 5, pp 530–534

Effect of strict blood glucose control on residual B-cell function in insulin-dependent diabetics

  • S. Madsbad
  • T. Krarup
  • L. Regeur
  • O. K. Faber
  • C. Binder
Originals

Summary

In 14 insulin dependent diabetics past their initial remission period B-cell function was evaluated using a test meal before and after 1 week of strict blood glucose control, and again 3 weeks later when the patients were outpatients on conventional therapy. Eight patients with fasting C-peptide above 0.07 nmol/l improved their B-cell function significantly (p<0.05) during the period of strict blood glucose control. However, the improvement was of short duration and was absent 3 weeks later in most patients. Six patients with fasting C-peptide below or equal to 0.07 nmol/l had no significant improvement in B-cell function during the period of strict control. The study shows that B-cell function and degree of blood glucose control are related in patients with fasting C-peptide above 0.07 nmol/l, and that B-cell function can change within days.

Key words

Glycaemic control B-cell function insulin-dependent diabetics C-peptide endogenous insulin secretion 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ludvigsson J, Heding LG (1978) Beta-cell function in children with diabetes. Diabetes 27 [Suppl 1]: 230–234Google Scholar
  2. 2.
    Krarup T, Madsbad S, Regeur L, Binder C, Faber O (1979) Beta-cell function during initial treatment in insulin dependent diabetics. Acta Endocrinol [Suppl] (Kbh) 277: 44Google Scholar
  3. 3.
    Faber OK, Binder C (1977) Plasma C-peptide during the first year of insulin-dependent diabetes mellitus. Int Congr Series No 413. Excerpta Medica, Amsterdam, p 149–154Google Scholar
  4. 4.
    Block MB, Rosenfield RL, Mako ME, Steiner DF, Rubenstein AH (1973) Sequential changes in beta-cell function in insulin-treated diabetic patients assessed by C-peptide immunoreactivity. N Engl J Med 288: 1144–1148Google Scholar
  5. 5.
    Hernandez A, Zorilla E, Gershberg H (1968) Serum-insulin in remission of juvenile diabetes. Lancet II: 223Google Scholar
  6. 6.
    Weber B (1972) Glucose stimulated insulin secretion during remission of juvenile diabetes. Diabetologia 189–195Google Scholar
  7. 7.
    Ludvigsson J, Heding LG, Larson Y (1977) C-peptide in juvenile diabetics beyond the post-initial remission period. Acta Paediatr Scand 66: 177–184Google Scholar
  8. 8.
    Grajwer LA, Pildes RS, Horwitz DL, Rubenstein AH (1977) Control of juvenile diabetes mellitus and its relationship to endogenous insulin secretion as measured by C-peptide immunoreactivity. J Pediatr 90: 42–48Google Scholar
  9. 9.
    Gonen B, Goldman J, Baldwin D, Goldberg RB, Ryan WG, Blix PM, Schanzlin D, Frits KH, Rubenstein AH (1979) Metabolic control in diabetic patients. Effect of insulin-secretory reserve (measured by plasma C-peptide levels) and circulating insulin antibodies. Diabetes 28: 749–753Google Scholar
  10. 10.
    Madsbad S, Alberti KGMM, Binder C, Faber OK, Hudson A, Krarup T, Regeur L (1979) Role of residual insulin secretion in protecting against ketoacidosis in insulin-dependent diabetes. Br Med J II: 1257–1259Google Scholar
  11. 11.
    Mirouze J, Selam JL, Phan TC, Mendoza E, Orsetti A (1978) Sustained insulin-induced remissions of juvenile diabetes by means of an external pancreas. Diabetologia 14: 223–227Google Scholar
  12. 12.
    Natvig H (1956) Nye Høyde —Vekttabeller for norske kvinner og menn. Landsforeningen for kosthold og helse, OsloGoogle Scholar
  13. 13.
    Faber OK, Hagen C, Binder C, Markussen J, Naithani VK, Blix PM, Kuzuya H, Horwitz DL, Rubenstein AH (1978) Kinetics of human connecting peptide in normal and diabetic subjects. J Clin Invest 62: 197–203Google Scholar
  14. 14.
    Trinder P (1969) Determination of blood glucose using 4-aminophenazone as oxygen acceptor. J Clin Pathol 22: 246Google Scholar
  15. 15.
    Heding LG (1975) Radioimmunological determination of human C-peptide in serum. Diabetologia 11: 541–548Google Scholar
  16. 16.
    Faber OK, Markussen J, Naithani VK, Binder C (1976) Production of antisera to synthetic benzyloxycarbonyl-C-peptide of human proinsulin. Hoppe-Seylers Z Physiol Chem 357: 751–757Google Scholar
  17. 17.
    Faber OK, Binder C, Markussen J, Heding LG, Naithani VK, Kuzuya H, Blix P, Horwitz DL, Rubenstein AH (1978) Characterization of seven C-peptide antisera. Diabetes 27 [Suppl 1]: 170–177Google Scholar
  18. 18.
    Schlichtkrull J, Munck O, Jersild M (1965) The M-value, an index of blood-sugar control in diabetics. Acta Med Scand 177: 95–102Google Scholar
  19. 19.
    Hendriksen C, Faber OK, Drejer J, Binder C (1977) Prevalence of residual B-cell function in insulin-treated diabetics evaluated by the plasma C-peptide response to intravenous glucagon. Diabetologia 13: 615–619Google Scholar
  20. 20.
    Faber OK, Wahren J, Ferrannini E, Binder C, DeFronzo RA (1978) Direct effect of insulin on the beta-cell function. Diabetologia 15: 230Google Scholar
  21. 21.
    Turner RC, McCarthy ST, Holman RR, Harris E (1976) Betacell function improved by supplementing basal insulin secretion in mild diabetes. Br Med J I: 1252–1254Google Scholar
  22. 22.
    Pickup JC, Keen H, Parsons JA, Alberti KGMM, Rowe AS (1979) Continous subcutaneous insulin infusion: improved blood glucose and intermediary-metabolite control in diabetics. Lancet I: 1255–1258Google Scholar
  23. 23.
    Tanborlane WV, Sherwin RS, Genel M, Felig P (1979) Reduction to normal of plasma glucose in juvenile diabetes by subcutaneous administration of insulin with a portable infusion pump. N Engl J Med 11: 573–578Google Scholar

Copyright information

© Springer-Verlag 1981

Authors and Affiliations

  • S. Madsbad
    • 1
  • T. Krarup
    • 1
  • L. Regeur
    • 1
  • O. K. Faber
    • 1
  • C. Binder
    • 1
  1. 1.Hvidøre HospitalKlampenborgDenmark

Personalised recommendations